Wall Street Zen Upgrades Artiva Biotherapeutics (NASDAQ:ARTV) to Hold

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

Several other equities analysts have also issued reports on ARTV. Needham & Company LLC reissued a "buy" rating and issued a $41.00 price target on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, May 26th. Wedbush lifted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an "outperform" rating in a report on Monday, May 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Finally, HC Wainwright increased their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a "buy" rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $39.00.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ:ARTV opened at $11.27 on Friday. The firm's 50 day simple moving average is $9.36 and its 200 day simple moving average is $7.74. Artiva Biotherapeutics has a fifty-two week low of $2.22 and a fifty-two week high of $14.53. The company has a market capitalization of $278.59 million, a price-to-earnings ratio of -3.42 and a beta of 2.16.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.63). Equities research analysts expect that Artiva Biotherapeutics will post -2.45 earnings per share for the current year.

Insider Activity at Artiva Biotherapeutics

In related news, Director Ra Capital Management, L.P. acquired 24,944 shares of the business's stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average cost of $9.93 per share, with a total value of $247,693.92. Following the transaction, the director owned 17,329,570 shares of the company's stock, valued at $172,082,630.10. The trade was a 0.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 9,907,958 shares of company stock worth $107,688,019 and have sold 53,040 shares worth $477,890. 21.40% of the stock is currently owned by insiders.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of ARTV. State of Wyoming bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $45,000. Bank of America Corp DE raised its holdings in shares of Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the third quarter worth $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics in the first quarter worth $131,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Artiva Biotherapeutics during the fourth quarter worth $91,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source